Literature DB >> 18022963

Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis.

Paolo Nanni1, Daniela Parisi, Giulia Roda, Monica Casale, Andrea Belluzzi, Enrico Roda, Lloyd Mayer, Aldo Roda.   

Abstract

The identification of new biomarkers or a disease-related protein fingerprint for inflammatory bowel diseases (IBDs) represents a major task in the diagnosis, prognosis and pharmacological therapy. To address these issues, a simple and rapid analytical proteomic method for serum protein profiling based on selective beads-based solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and chemometric data analysis was developed. Serum proteins from healthy subjects (22) and patients with Crohn's disease (15) and ulcerative colitis (26) were selectively extracted according to reversed-phase (C18), strong anion-exchange (SAX) and metal ion affinity (IDA-Cu(II)) principles. This approach allowed enrichment of serum proteins/peptides due to the high interaction surface between analytes and the solid phase and high recovery due to the elution step performed directly on the MALDI-target plate. The MALDI-TOF MS serum protein profiles were acquired and, after a data pre-processing step, analyzed by linear discriminant analysis (LDA), a chemometric classification technique, in order to classify serum samples among healthy subjects and patients with inflammatory bowel diseases (IBDs). Since the high number of variables in the MALDI spectra (more than 16000 m/z values) prevents the use of LDA, the variables were reduced to 10-20 by features selection, thus allowing the evaluation of a pattern of m/z values with high discriminant power. Serum protein profiles obtained by reversed-phase extraction and the selection of 20 m/z values gave the best overall prediction ability (96.9%). The recognition of these m/z values may allow the identification of protein biomarkers involved in IBDs. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022963     DOI: 10.1002/rcm.3323

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  17 in total

Review 1.  Current advantages in the application of proteomics in inflammatory bowel disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; George Theodoropoulos; George Zografos
Journal:  Dig Dis Sci       Date:  2012-06-28       Impact factor: 3.199

Review 2.  Current application of proteomics in biomarker discovery for inflammatory bowel disease.

Authors:  Patrick Py Chan; Valerie C Wasinger; Rupert W Leong
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

Review 3.  Biomarkers in inflammatory bowel disease: current practices and recent advances.

Authors:  Heba N Iskandar; Matthew A Ciorba
Journal:  Transl Res       Date:  2012-02-01       Impact factor: 7.012

4.  Serum protein profiling of adults and children with Crohn disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; Aggeliki Papadopoulou; Athanassios K Anagnostopoulos; George Karamanolis; George E Theodoropoulos; Amosy M'Koma; George T Tsangaris
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-01       Impact factor: 2.839

Review 5.  Laboratory markers in ulcerative colitis: Current insights and future advances.

Authors:  Michele Cioffi; Antonella De Rosa; Rosalba Serao; Ilaria Picone; Maria Teresa Vietri
Journal:  World J Gastrointest Pathophysiol       Date:  2015-02-15

Review 6.  Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine.

Authors:  Emilie Viennois; Yuan Zhao; Didier Merlin
Journal:  Inflamm Bowel Dis       Date:  2015-10       Impact factor: 5.325

Review 7.  Recent Advances in the Etiopathogenesis of Inflammatory Bowel Disease: The Role of Omics.

Authors:  Eleni Stylianou
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

Review 8.  Applications of proteomics in the study of inflammatory bowel diseases: Current status and future directions with available technologies.

Authors:  Philip Alex; Marjan Gucek; Xuhang Li
Journal:  Inflamm Bowel Dis       Date:  2009-04       Impact factor: 5.325

Review 9.  New serological biomarkers of inflammatory bowel disease.

Authors:  Xuhang Li; Laurie Conklin; Philip Alex
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

10.  Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic Perspective.

Authors:  Valerie C Wasinger; Yunki Yau; Xizi Duo; Ming Zeng; Beth Campbell; Sean Shin; Raphael Luber; Diane Redmond; Rupert W L Leong
Journal:  Mol Cell Proteomics       Date:  2015-11-03       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.